NewsRoom Articles - PsychedelicNewsWire (PNW)

ThursdayJun 12, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is facing a severe ketamine shortage, prompting NRx to seek priority FDA review. NRX-100 eliminates benzethonium chloride, aligning with U.S. health initiatives to remove toxic preservatives. The company plans to petition the FDA to remove benzethonium chloride from all intravenous ketamine products. The filing complements the company’s NDA for NRX-100 for suicidal depression, with a PDUFA date expected in late 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a preservative-free formulation…

ThursdayJun 05, 2025 11:15 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics. HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer. NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical…

WednesdayMay 28, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined with a prior strategic investment, for which a financing term sheet has also been signed, the total financing investment, assuming both are closed, represents an expected $10.3 million for HOPE acquisition funding, supporting initial acquisitions of Dura Medical, Kadima, and NeuroSpa clinics. The expanding HOPE clinic network will deliver neuroplastic therapies for depression and PTSD, including ketamine and TMS. NRx continues regulatory progress for NRX-100 (IV ketamine) and NRX-101 (oral bipolar depression therapy). The FDA waived NRx’s $4.3 million drug application fee, and patents could…

FridayMay 23, 2025 10:30 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network of psychiatric clinics. The acquisition brings profitability and is expected to be accretive to both revenue and EBITDA. Kadima’s founder and medical director, Dr. David Feifel, a leader in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer. NRx’s pipeline includes investigational drugs for suicidal bipolar depression and chronic pain. HOPE is targeting 30 clinic acquisitions by the end of 2025, projecting $100M in annual revenue. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics, Inc., a medical…

TuesdayMay 20, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central nervous system disorders. The company’s lead candidate, NRX-100 (preservative free IV ketamine), NDA in process with the FDA, has been granted Fast Track designation by the FDA for acute suicidal depression, and a patent for this novel formulation has been filed with the U.S. Patent and Trademark Office. NRX-101 (oral D-cycloserine/lurasidone), has received FDA Breakthrough Therapy designation, expediting its development. HOPE Therapeutics, NRx’s interventional psychiatry subsidiary, is targeting $100M in forward looking revenue by year-end 2025, through development of a national clinic network treating suicidal depression,…

MondayMay 19, 2025 2:30 pm

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he’s pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell…

WednesdayMar 26, 2025 10:00 am

Study Shows Psychedelic Use Could Lower Chances of Suffering Frequent Headaches

According to a recent study, individuals who have used classic psychedelics like LSD or psilocybin are less prone to episodes of bad headaches. These results, the study authors say, suggest classic psychedelics could in future be explored for their prophylactic potential against headache disorders. The researchers at Karolinska Institutet located in Stockholm, Sweden obtained data for the period 1999-2000. This data was gathered as part of the 1958 British Child Development Study, a longitudinal cohort study tracking individuals who were born in Britain in 1958 in one week of the month of March. They specifically obtained 11,419 pieces of data…

MondayMar 24, 2025 10:00 am

More People are Microdosing Psychedelics to Ease the Challenges of Parenting

There is a growing trend in which parents take tiny doses of psychedelics like LSD and psilocybin in order to cope with the challenges of parenting. Is microdosing psychedelics for these reasons a breakthrough on parenting, or is it simply reckless nonsense? A German father going by the pseudonym ‘Arno Kanter’ claims that microdosing LSD has enabled him to see things like his daughter aged 2 years and he can genuinely be enthusiastic and adventurous when he takes her out to a local park. Previously, he would feign interest in the things she pointed out and would be too exhausted…

WednesdayMar 19, 2025 10:00 am

DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers

Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to study MDMA with a focus on troops on active duty. The money will be provided by the U.S. Department of Defense (DOD). The hallucinogen will be given to active-duty military personnel diagnosed with mild or moderate PTSD. The objective is to study the ways in which the psychological flexibility triggered by the drug aids in the healing of patients. Another $4.9 million from the DOD will go to a collaborative study conducted by teams at STRONG STAR and Emory University. STRONG STAR, a training and…

MondayMar 17, 2025 10:00 am

Study Finds That the Mental Wellbeing Effects of Psilocybin Vary by Race

A new study has found that while all ethnic and racial groups can benefit from using psilocybin, some effects vary depending on the ethnic or racial group that an individual belongs to. More specifically, the mental flexibility and spiritual wellbeing improvements resulting from psilocybin use aren’t as pronounced and don’t persist for long among individuals of color when compared to these same effects in White people. The researchers were motivated to conduct this study after observing that the participants in most studies on psychedelics tended to be predominantly White. The team wondered whether the findings of such studies could be…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000